372 related articles for article (PubMed ID: 30816967)
1. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?
Jenks JD; Mehta SR; Hoenigl M
Med Mycol; 2019 Apr; 57(Supplement_2):S168-S178. PubMed ID: 30816967
[TBL] [Abstract][Full Text] [Related]
2. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
3. New pharmacological opportunities for the treatment of invasive mould diseases.
Ledoux MP; Toussaint E; Denis J; Herbrecht R
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
[TBL] [Abstract][Full Text] [Related]
4. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
Maertens JA; Girmenia C; Brüggemann RJ; Duarte RF; Kibbler CC; Ljungman P; Racil Z; Ribaud P; Slavin MA; Cornely OA; Peter Donnelly J; Cordonnier C; ;
J Antimicrob Chemother; 2018 Dec; 73(12):3221-3230. PubMed ID: 30085172
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management.
Girmenia C; Busca A; Candoni A; Cesaro S; Luppi M; Nosari AM; Pagano L; Rossi G; Venditti A; Aversa F
Med Mycol; 2019 Apr; 57(Supplement_2):S127-S137. PubMed ID: 30816979
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
8. Invasive mould infections in the ICU setting: complexities and solutions.
Bassetti M; Bouza E
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
[TBL] [Abstract][Full Text] [Related]
9. Clinical considerations in the early treatment of invasive mould infections and disease.
Mercier T; Maertens J
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i29-i38. PubMed ID: 28355465
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
11. Changing epidemiology of rare mould infections: implications for therapy.
Malani AN; Kauffman CA
Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
14. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
15. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
17. Our 2015 approach to invasive pulmonary aspergillosis.
Liss B; Vehreschild JJ; Bangard C; Maintz D; Frank K; Grönke S; Michels G; Hamprecht A; Wisplinghoff H; Markiefka B; Hekmat K; Vehreschild MJ; Cornely OA
Mycoses; 2015 Jun; 58(6):375-82. PubMed ID: 25808916
[TBL] [Abstract][Full Text] [Related]
18. Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients.
Coussement J; Lindsay J; Teh BW; Slavin M
Curr Opin Infect Dis; 2021 Aug; 34(4):297-306. PubMed ID: 34039878
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
20. Real-life use of isavuconazole outside the hematological wards.
Scabini S; Lupia T; Angilletta R; De Rosa FG; Corcione S
Eur J Intern Med; 2019 Dec; 70():e10-e12. PubMed ID: 31526649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
